Logo image of 2HQ.DE

TILRAY BRANDS INC (2HQ.DE) Stock Fundamental Analysis

FRA:2HQ - US88688T1007 - Common Stock

0.9422 EUR
-0.06 (-5.92%)
Last: 9/8/2025, 7:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to 2HQ. 2HQ was compared to 50 industry peers in the Pharmaceuticals industry. 2HQ has a bad profitability rating. Also its financial health evaluation is rather negative. 2HQ is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year 2HQ has reported negative net income.
2HQ had a negative operating cash flow in the past year.
In the past 5 years 2HQ always reported negative net income.
In the past 5 years 2HQ reported 4 times negative operating cash flow.
2HQ.DE Yearly Net Income VS EBIT VS OCF VS FCF2HQ.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500M -1B -1.5B -2B

1.2 Ratios

2HQ has a Return On Assets of -105.42%. This is amonst the worse of the industry: 2HQ underperforms 90.00% of its industry peers.
2HQ has a worse Return On Equity (-144.68%) than 82.00% of its industry peers.
Industry RankSector Rank
ROA -105.42%
ROE -144.68%
ROIC N/A
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
2HQ.DE Yearly ROA, ROE, ROIC2HQ.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 -200 -300

1.3 Margins

2HQ has a Gross Margin of 29.29%. This is in the lower half of the industry: 2HQ underperforms 78.00% of its industry peers.
In the last couple of years the Gross Margin of 2HQ has grown nicely.
The Profit Margin and Operating Margin are not available for 2HQ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 29.29%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.37%
GM growth 5YN/A
2HQ.DE Yearly Profit, Operating, Gross Margins2HQ.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200

More info and screens

3

2. Health

2.1 Basic Checks

2HQ does not have a ROIC to compare to the WACC, probably because it is not profitable.
2HQ has more shares outstanding than it did 1 year ago.
2HQ has more shares outstanding than it did 5 years ago.
2HQ has a worse debt/assets ratio than last year.
2HQ.DE Yearly Shares Outstanding2HQ.DE Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
2HQ.DE Yearly Total Debt VS Total Assets2HQ.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

2HQ has an Altman-Z score of -1.51. This is a bad value and indicates that 2HQ is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of 2HQ (-1.51) is worse than 78.00% of its industry peers.
A Debt/Equity ratio of 0.19 indicates that 2HQ is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.19, 2HQ is in the better half of the industry, outperforming 78.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z -1.51
ROIC/WACCN/A
WACC8.93%
2HQ.DE Yearly LT Debt VS Equity VS FCF2HQ.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

2.3 Liquidity

2HQ has a Current Ratio of 2.46. This indicates that 2HQ is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 2.46, 2HQ is doing good in the industry, outperforming 80.00% of the companies in the same industry.
A Quick Ratio of 1.49 indicates that 2HQ should not have too much problems paying its short term obligations.
The Quick ratio of 2HQ (1.49) is better than 80.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.46
Quick Ratio 1.49
2HQ.DE Yearly Current Assets VS Current Liabilites2HQ.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

2HQ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -490.77%.
The Revenue has been growing slightly by 4.11% in the past year.
2HQ shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.52% yearly.
EPS 1Y (TTM)-490.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3150%
Revenue 1Y (TTM)4.11%
Revenue growth 3Y9.33%
Revenue growth 5Y37.52%
Sales Q2Q%-2.33%

3.2 Future

The Earnings Per Share is expected to grow by 15.55% on average over the next years. This is quite good.
2HQ is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.43% yearly.
EPS Next Y92.7%
EPS Next 2Y39.41%
EPS Next 3Y26.96%
EPS Next 5Y15.55%
Revenue Next Year3.8%
Revenue Next 2Y4.23%
Revenue Next 3Y4.1%
Revenue Next 5Y4.43%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
2HQ.DE Yearly Revenue VS Estimates2HQ.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
2HQ.DE Yearly EPS VS Estimates2HQ.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 2HQ. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 2HQ. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
2HQ.DE Price Earnings VS Forward Price Earnings2HQ.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, 2HQ is valued a bit more expensive than the industry average as 72.00% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 47.54
2HQ.DE Per share data2HQ.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

2HQ's earnings are expected to grow with 26.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.41%
EPS Next 3Y26.96%

More info and screens

0

5. Dividend

5.1 Amount

2HQ does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TILRAY BRANDS INC

FRA:2HQ (9/8/2025, 7:00:00 PM)

0.9422

-0.06 (-5.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-28 2025-07-28/amc
Earnings (Next)10-08 2025-10-08/bmo
Inst Owners9.13%
Inst Owner ChangeN/A
Ins Owners0.29%
Ins Owner ChangeN/A
Market Cap1.04B
Analysts72.5
Price Target0.83 (-11.91%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2749.13%
Min EPS beat(2)-5362.97%
Max EPS beat(2)-135.29%
EPS beat(4)0
Avg EPS beat(4)-1413.07%
Min EPS beat(4)-5362.97%
Max EPS beat(4)-8.93%
EPS beat(8)1
Avg EPS beat(8)-730.51%
EPS beat(12)1
Avg EPS beat(12)-762.79%
EPS beat(16)3
Avg EPS beat(16)-613.4%
Revenue beat(2)0
Avg Revenue beat(2)-10.25%
Min Revenue beat(2)-13.28%
Max Revenue beat(2)-7.23%
Revenue beat(4)0
Avg Revenue beat(4)-8.93%
Min Revenue beat(4)-13.28%
Max Revenue beat(4)-4.66%
Revenue beat(8)0
Avg Revenue beat(8)-5.77%
Revenue beat(12)1
Avg Revenue beat(12)-3.94%
Revenue beat(16)1
Avg Revenue beat(16)-4.24%
PT rev (1m)-31.09%
PT rev (3m)-31.63%
EPS NQ rev (1m)35.71%
EPS NQ rev (3m)25%
EPS NY rev (1m)40%
EPS NY rev (3m)30%
Revenue NQ rev (1m)-0.78%
Revenue NQ rev (3m)-4.7%
Revenue NY rev (1m)-1.38%
Revenue NY rev (3m)-3.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.48
P/FCF N/A
P/OCF N/A
P/B 0.8
P/tB 1.65
EV/EBITDA 47.54
EPS(TTM)-1.31
EYN/A
EPS(NY)-0.1
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0.64
BVpS1.17
TBVpS0.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -105.42%
ROE -144.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 29.29%
FCFM N/A
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.37%
GM growth 5YN/A
F-Score4
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA 11.15
Cap/Depr 24.66%
Cap/Sales 4.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.46
Quick Ratio 1.49
Altman-Z -1.51
F-Score4
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)21.23%
Cap/Depr(5y)65.02%
Cap/Sales(3y)3.68%
Cap/Sales(5y)7.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-490.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3150%
EPS Next Y92.7%
EPS Next 2Y39.41%
EPS Next 3Y26.96%
EPS Next 5Y15.55%
Revenue 1Y (TTM)4.11%
Revenue growth 3Y9.33%
Revenue growth 5Y37.52%
Sales Q2Q%-2.33%
Revenue Next Year3.8%
Revenue Next 2Y4.23%
Revenue Next 3Y4.1%
Revenue Next 5Y4.43%
EBIT growth 1Y-11.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year109.68%
EBIT Next 3Y29.62%
EBIT Next 5Y17.51%
FCF growth 1Y-111.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-206.1%
OCF growth 3YN/A
OCF growth 5YN/A